Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer
1. APVO stock surged 137.2% with high trading volume. 2. New data from RAINIER trial shows 85% remission in AML patients. 3. No CRS observed; mipletamig demonstrates strong safety profile. 4. Direct offering of $8 million at $3.25 per share announced. 5. Unique immunotherapy approach positions APVO favorably in AML market.